Horizon Pharma stock soars 12% premarket on positive eye-disease treatment trial
Horizon Pharma plc shares HZNP, +4.60% soared 17% in premarket trade Thursday, after the company announced positive results in a late-stage trial of a treatment for active thyroid eye disease, or TED. The company said the phase 3 trial of teprotumumab met its primary endpoint of improving proptosis, or bulging of the eye compared with placebo, with 82.9% of patients showing improvement compared with 9.5% of placebo patients.
Have breaking news sent to your inbox. Subscribe to MarketWatch's free Bulletin emails. Sign up here.
Malaysia Latest News, Malaysia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Pharma giants are betting billions on gene therapies that could fundamentally change how we treat diseasesRecent deals like Roche's $4.8 billion bet on Spark and Novartis' $8.7 billion acquisition of AveXis show that big pharma is betting big on gene therapy.
Read more »
GE-Danaher pharma deal is a win-win remedyCEO Larry Culp is unloading the conglomerate’s biologics unit to his old employer for $21 bln. It’s his boldest downsizing move yet and will help cut leverage. Danaher gains scale in its health business at a reasonable price while Culp needed a sale, not necessarily top dollar.
Read more »
Aurora Cannabis to acquire 51% stake in Portugal's Gaia Pharma, set up medical cannabis facility
Read more »
These Senators Received The Biggest Checks From Pharma Companies Testifying TuesdaySeven pharma executives are expected to face tough questions about the price of their drugs Tuesday before the U.S. Senate Finance Committee. They’ll also be answering to a group that’s received hundreds of thousands of dollars in campaign contributions from their own companies’ PACs.
Read more »
Grassley to Big Pharma: 'I'm sick and tired of the blame game'Sen. Chuck Grassley opened a hearing into the rising costs of prescription medicine on Tuesday by blasting Big Pharma, saying that skyrocketing prices are hurting Americans and that the time has come for a reckoning. 'I'm sick and tired of the blame game.'
Read more »
Big Pharma companies defending skyrocketing prices on the HillAmericans spent more than $300 billion on prescription drugs last year alone and that’s set to get even higher. Right now, the heads of seven major pharmaceutical companies are on Capitol Hill, trying to defend the skyrocketing costs. Ali Velshi and Stephanie Ruhle are joined by Hippo’s Chief Patient Advocate, MJ Hegar, who claims to have the answer to all of this.
Read more »
Friction between drugmakers, GOP intensifies at hearing on pharma pricingThe drug industry may no longer be able to take congressional Republicans' support for granted after the Senate Finance Committee grilled seven company executives on their pricing practices on Tuesday
Read more »
Big Pharma Survives Hearings, but Watch OutHeard on the Street: The Senate's hearing on drug pricing didn’t cause much of a stir on Wall Street, but investors in drug stocks would be wise to note the tough tone
Read more »
In Senate testimony, pharma executive admits drug prices hit poor the hardestTop execs from 7 major pharmaceutical companies told a Senate committee that they could not commit to lower the price of commonly used prescription drugs even as they admitted that they control those prices.
Read more »